For the quarter ending 2025-12-31, RGBP made $59,065 in revenue. -$967,853 in net income. Net profit margin of -1638.62%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Net revenue | 59,065 | 59,215.5 | 59,065 | 59,065 |
| Research and development | 210,000 | 3,908.333 | 0 | - |
| General and administrative | 231,925 | 15,534 | 30,697 | 13,348 |
| Consulting and professional fees | 153,764 | 107,536.5 | 46,624 | 136,566 |
| Rent | 15,000 | 22,500 | 22,500 | 22,500 |
| Total operating expenses | 610,689 | 151,433 | 99,821 | 172,414 |
| Loss from operations | -551,624 | -92,217.5 | -40,756 | -113,349 |
| Interest expense | 26,553 | 55,659.5 | 24,638 | 22,329 |
| Interest expense attributable to amortization of discount | 8,850 | 13,435 | 12,639 | 12,639 |
| Derivative income (expense) | -380,826 | -357,616 | -89,259 | 128,963 |
| Penalties | 0 | 12,500 | - | - |
| Financing fees | 0 | - | - | - |
| Total other income (expense), net | -416,229 | -451,710.5 | -126,536 | 93,995 |
| Net loss before income taxes | -967,853 | -543,928 | -167,292 | -19,354 |
| Income tax provision | 0 | 0 | 0 | - |
| Net loss | -967,853 | -543,928 | -167,292 | -19,354 |
| Net loss per common share, basic | -0.01 | -0.02 | -0.01 | 0 |
| Net loss per common share, diluted | -0.01 | -0.02 | -0.01 | 0 |
| Number of weighted average shares - basic | 99,609,650 | -10,892,620 | 23,752,506 | 21,554,704 |
| Number of weighted average shares - diluted | 99,609,650 | -10,892,620 | 23,752,506 | 21,554,704 |
Regen BioPharma Inc (RGBP)
Regen BioPharma Inc (RGBP)